With more than 20 COVID-19 vaccines in clinical trials, the collaboration between Johnson & Johnson and Beth Israel Deaconess in Boston is getting $1 billion in U.S. funding. Lead researcher Dan Barouch charts the road ahead. Watch Article
6 companies aside from Johnson & Johnson are in phase 3 of human trials, but the scientists working round the clock at the company’s lab in Boston could see a vaccine by early next year.
An experimental coronavirus vaccine developed by Johnson & Johnson protected monkeys from infection in a new study. It is the second vaccine candidate to show promising results in monkeys this week. Read Article
The pharmaceutical giant will now begin testing its vaccine candidate on humans. Read Article
Johnson & Johnson on Thursday kicked off U.S. human safety trials for its COVID-19 vaccine after releasing details of a study in monkeys that showed its best-performing vaccine candidate offered strong protection in a single dose. Read Article
Dr. Barouch spoke to the Boston Globe about our COVID-19 vaccine developments entering early-stage clinical trial in people. Read Article
Scientists have created candidate vaccines, which eventually could protect billions of people from COVID-19, with astonishing speed, compressing scientific efforts that usually take years into months. But the leader of a key drug trial said Tuesday that the blistering research pace has nonetheless been too slow to catch the coronavirus. Read Article
Dr. Kathryn Stephenson co-wrote this OP-ED for the Washington Post. Read Article
ABCNEWS
HMS
